Maintained by Sreepriya Prasannan

MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist

Compiled from ClinicalTrials.gov and CTIS registry records · Last verified 26 Sep 2026 · Editorial standards

At a glance

Nanjing Medical University is the lead sponsor of 34 current clinical trials in our China register. 17 are recruiting patients now. The most common phase is Not applicable. The drugs named most often in its trials are Rosuvastatin, Ubiquinone and Ulinastatin. The most-studied condition is Cardiopulmonary Bypass.

ClinicalTrials.gov trials by status

Recruiting1750%
Not yet open1029%
Active, closed13%
By invitation618%

Trials by phase

Not applicable2368%
Observational926%
Phase 313%
Phase 2/313%

Clinical trials sponsored by Nanjing Medical University

34 on ClinicalTrials.gov

Study	Phase	Status	Start	Registers
Diaphragmatic Function and Respiratory Drive in OSA and COPD NCT07003399 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea	Observational	Recruiting	2025-01	China
Additive Anti-inflammatory Action for Aortopathy & Arteriopathy NCT04398992 · ClinicalTrials.gov ↗ · Acute Aortic Syndrome	Observational	Recruiting	2016-01	China
Recurrent Liver Cancer: Reconceptualization and Reevaluation NCT06430983 · ClinicalTrials.gov ↗ · Recurrent Liver Cancer, Primary Liver Cancer	Observational	Recruiting	2024-07	China
Clinical Study for Dimethyl Fumarate in Preserving Islet β-Cell Function in Type 1 Diabetes Mellitus NCT07258394 · ClinicalTrials.gov ↗ · Type 1 Diabetes	Phase 3	Recruiting	2026-01	China
Effects and Mechanisms of Transcranial Direct Current Stimulation Combined With Dialectical Behavior Therapy Skills Training in Adults With Attention-Deficit/Hyperactivity Disorder NCT07565402 · ClinicalTrials.gov ↗ · Adult Attention Deficit Hyperactivity Disorder	Not applicable	Recruiting	2026-04	China
Protective Effect of CoQ10 Against Negative Inflammatory Response and Organ Dysfunction in Cardiovascular Surgery (PANDA V) NCT04444349 · ClinicalTrials.gov ↗ · Cardiovascular Disease Drug: Ubiquinone	Not applicable	Recruiting	2021-02	China
Using Single and Combined Nudge Strategies to Promote Healthier Beverage Intake Among College Students NCT07625969 · ClinicalTrials.gov ↗ · Obesity, Food Selection	Not applicable	Recruiting	2026-07	China
Prospective Study of Classification and Activity Assessment of Psoriatic Arthritis Based on Power Doppler (PD) Ultrasonography (PDUS) NCT06730334 · ClinicalTrials.gov ↗ · Psoriatic Arthritis, Secukinumab, Ultrasonography	Observational	Recruiting	2023-09	China
Neural Changes in Stroke Patients During Challenging Walking Tasks. NCT06764290 · ClinicalTrials.gov ↗ · Stroke	Observational	Recruiting	2024-04	China
The Effect of Interventions for Health Behaviors in Hypertensive Patients NCT06640751 · ClinicalTrials.gov ↗ · Hypertension, Health Behavior, Public Health	Not applicable	Recruiting	2024-10	China
Prediction of Risk of Vascular Structural Damage in Patients With Large Vessel Vasculitis (LVV) Based on PET/MRA Image Evaluation System NCT06824714 · ClinicalTrials.gov ↗ · Large Vessel Vasculitis	Observational	Recruiting	2024-01	China
Undergraduate Nursing Intern Cohort Study NCT07682493 · ClinicalTrials.gov ↗ · Occupational Disidentification	Observational	Recruiting	2026-06	China
Optic Nerve Injury in Obstructive Sleep Apnea Patients NCT06748703 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea (OSA), Ischemic Optic Neuropathy/Optic Nerve Stroke	Not applicable	Recruiting	2025-01	China
Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes NCT07548996 · ClinicalTrials.gov ↗ · Type 1 Diabetes Mellitus	Phase 2/3	Recruiting	2026-04	China
Protective Effect of Sivelestat Against Negative Pulmonary Function and Organ Dysfunction After Cardiovascular Surgery (PANDA VI) NCT06195267 · ClinicalTrials.gov ↗ · Aortic Dissection, Systemic Inflammatory Response Syndrome, Cardiovascular Diseases (CVD)	Not applicable	Recruiting	2024-07	China
Impact of Pre-Ablation Prehabilitation on Clinical Outcomes and Cardiorespiratory Fitness in Atrial Fibrillation Patients NCT07270757 · ClinicalTrials.gov ↗ · Atrial Fibrillation (AF)	Not applicable	Recruiting	2025-02	China
Protective Effect of Statin Against Negative Cardiovascular Remodeling and Organ Dysfunction After Acute Aortic Syndrome Surgery (PANDA III) NCT04699279 · ClinicalTrials.gov ↗ · Acute Aortic Syndrome, Aortopathy Drug: Rosuvastatin	Not applicable	Recruiting	2021-01	China
Protective Effect of Angong Niuhuang Against Negative Inflammatory Response and Neurologic Dysfunction After Cardiovascular Surgery NCT06723366 · ClinicalTrials.gov ↗ · Cardio-pulmonary Bypass, Cardiovascular Surgery, Cerebral Protection	Not applicable	Not yet open	2025-01	China
Vitamin B Supplementation for Patients Undergoing Cardiovascular Surgery NCT07348328 · ClinicalTrials.gov ↗ · Cardiovascular Surgical Procedures, Major Adverse Cardiovascular Events (MACE)	Not applicable	Not yet open	2026-02	China
Concomitant Tricuspid Repair in Patients With Left Heart Surgery NCT05595187 · ClinicalTrials.gov ↗ · Tricuspid Regurgitation, Mitral Regurgitation, Cardiopulmonary Bypass	Not applicable	Not yet open	2024-05	China
Protective Effect of RIPC Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery (Panda VII) NCT06707350 · ClinicalTrials.gov ↗ · Cardiopulmonary Bypass, Cardiovascular Diseases, Inflammatory Response During Cardiac Surgery	Not applicable	Not yet open	2024-12	China
Protective Effect of EECP Against Negative Inflammatory Response and Organ Dysfunction After Cardiovascular Surgery NCT06728605 · ClinicalTrials.gov ↗ · Coronary Heart Disease (CHD), Cardio-pulmonary Bypass, Congestive Heart Failure Chronic	Not applicable	Not yet open	2025-12	China
Protective Effect of PCSK9 Inhibitor Against Negative Inflammatory Response and Organ Dysfunction After Coronary Artery Bypass Grafting (PANDA VIII) NCT06730802 · ClinicalTrials.gov ↗ · Myocardial Ischaemic Syndrome, Coronary Heart Disease	Not applicable	Not yet open	2025-01	China
Precision OSA Therapy Based on Phenotypes and Endotypes NCT06825923 · ClinicalTrials.gov ↗ · Obstructive Sleep Apnea	Observational	Not yet open	2025-07	China
AI-assisted Subtyping-directed Precision Treatment in Acute Aortic Dissection NCT07382375 · ClinicalTrials.gov ↗ · Aortic Aneurysm and Dissection Drug: Ulinastatin	Not applicable	Not yet open	2027-12	China
Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery NCT07594509 · ClinicalTrials.gov ↗ · Cardio Vascular Disease, Cardiopulmonary Bypass Drug: Vericiguat	Not applicable	Not yet open	2026-05	China
Health Behavior Intervention for Colorectal Cancer Patients NCT07632313 · ClinicalTrials.gov ↗ · Colorectal Cancer	Not applicable	Not yet open	2026-06	China
Band Versus Ring for Tricuspid Regurgitation NCT04093297 · ClinicalTrials.gov ↗ · Tricuspid Regurgitation	Not applicable	By invitation	2025-01	China
Temporal Transformation Mechanism and Intervention Strategies of Frail-related Dietary Behaviors in Older Gastric Cancer Survivors NCT07176455 · ClinicalTrials.gov ↗ · Gastric Cancer (GC), Frailty in Adult Surgery	Observational	By invitation	2025-07	China
Protective Effect of Ulinastatin and Thymosin α1 Against Negative Immune Dysregulation and Organ Dysfunction After Acute Aortic Dissection Surgery (PANDA XI) NCT06966687 · ClinicalTrials.gov ↗ · Aortic Dissection, Aortic Dissection Aneurysm	Not applicable	By invitation	2025-04	China
Non-Invasive Brain-Computer Interface Combined With Transcranial Electrical Stimulation for Peripheral Facial PalsyStimulation in the Treatment of Peripheral Facial Palsy NCT07327710 · ClinicalTrials.gov ↗ · Peripheral Facial Palsy, Pulsed Radiofrequency, Brain-Computer Interface	Not applicable	By invitation	2025-11	China
Protective Effect of Probacine Against Negative Gut Metabolism and Organ Dysfunction After Cardiovascular Surgery (PANDA IV) NCT04444362 · ClinicalTrials.gov ↗ · Cardiovascular Disease, Cardiopulmonary Bypass	Not applicable	By invitation	2025-01	China
Effects of Repetitive Transcrannial Magnetic Stimulation on Non-Suicidal Self-Injury NCT06540300 · ClinicalTrials.gov ↗ · NSSI	Not applicable	By invitation	2024-06	China
Effects of the Combined Intervention of Exercise, Fruit, and Vitamin Supplementation on Frailty in Older Adults NCT06225271 · ClinicalTrials.gov ↗ · Frailty	Not applicable	Active, closed	2024-03	China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

Drugs in Nanjing Medical University trials

4 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

Rosuvastatin1 Ubiquinone1 Ulinastatin1 Vericiguat1

Conditions in Nanjing Medical University trials

54 conditions

Cardiopulmonary Bypass4 Tricuspid Regurgitation2Cardio-pulmonary Bypass2Obstructive Sleep Apnea2Acute Aortic Syndrome2Aortic Dissection2Cardiovascular Disease2Cardiovascular Surgery1Cerebral Protection1Brain Injury1Cardiovascular Surgical Procedures1Major Adverse Cardiovascular Events (MACE)1Gastric Cancer (GC)1Frailty in Adult Surgery1Mitral Regurgitation1 Cardiovascular Diseases1Inflammatory Response During Cardiac Surgery1Aortic Dissection Aneurysm1Recurrent Liver Cancer1Primary Liver Cancer1Type 1 Diabetes1Adult Attention Deficit Hyperactivity Disorder1Coronary Heart Disease (CHD)1Congestive Heart Failure Chronic1

By trial register

Register	Trials	Recruiting
Clinical trials in China	34	17

A trial with sites in more than one country appears in each of those registers.

Questions about Nanjing Medical University trials

How many clinical trials does Nanjing Medical University sponsor?

Nanjing Medical University is the lead sponsor of 34 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Nanjing Medical University trials recruiting?

Yes. 17 of its 34 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Nanjing Medical University testing?

Its current trials name 4 drugs and biologicals as interventions. The most frequent are Rosuvastatin (1), Ubiquinone (1), Ulinastatin (1) and Vericiguat (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.

Nanjing Medical University clinical trials